Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 102

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 8
Chunk 102
---
20(a) of the 1934 Act, on behalf of persons and entities who acquired our securities between January 27, 2022 and October 23, 2023 (the “Class Period”).  Plaintiffs allege that, during the Class Period, defendants made material misrepresentations or omissions regarding, among other things, the Company’s anticipated revenues for its bioprocessing business that artificially inflated the Company’s stock price.  Plaintiffs seek, among other things, damages in an unspecified amount, as well as fees and costs.  The Company moved to dismiss the amended complaint on February 27, 2024, and on August 4, 2025, the court granted in part and denied in part the Company’s motion to dismiss.Since January 2024, putative shareholder derivative cases have been filed in the United States District Court for the District of Delaware.  Those cases have been consolidated and are captioned In re Danaher Corporation Derivative Litigation, No. 1:24-cv-00091-GBW (the “Derivative Action”).  The Derivative Action names the Company as a nominal defendant and purports to bring claims on behalf of the Company against certain of the Company’s current and former directors and officers for alleged violations of the federal securities laws and breaches of their fiduciary duties, among other claims, in relation to substantially the same factual allegations as those made in the Hawkins Action.  These actions seek to recover unspecified damages and other relief on the Company’s behalf.  Proceedings in the Derivative Action have been stayed during the pendency of the Hawkins Action.  The outcomes of these legal proceedings remain uncertain and the Company is unable to reasonably estimate the possible loss or range of loss, if any.

For further discussion of the Company’s litigation and contingencies, refer to Note 17 of the Company’s financial statements as of and for the year ended December 31, 2024 included in the Company’s 2024 Annual Report.  

20

NOTE 13.  STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION

Stockholders’ EquityThe Company’s Board of Directors has approved the following programs to repurchase shares of the Company’s common stock: Name of programDate of Board of Director approvalNumber of shares of Company common stock approved for repurchaseNumber of shares remaining available for repurchase as of September 26, 20252013 Repurchase ProgramJuly 16, 201320,000,000 — 202